近日，东莞鹏佑生物科技有限公司(以下简称"鹏佑生物")宣布正式获得广东省农业农村厅颁发的《兽药GMP证书》及《兽药生产许可证》。这是东莞市颁发 的首张兽用诊断试剂GMP证书，标志着鹏佑生物在生产质量管理体系建设上迈出关键一步，为后续参与宠物医疗市场竞争提供了坚实保障。 | 編 를 | 企业名称 | 申请验收范围 | 申请验收 | 验收情况 | | | --- | --- | --- | --- | --- | --- | | | | | 类型 | | | | | | 免疫学生物诊断制品 (B 类）、分子生物学诊断制品 | 迁址重建 | 推荐为兽药GMP合 | 2 | | | | (B类) | | 格生产线 | | | 2 | 东莞鹏佑生物科技有 | 分子生物学类诊断制品（B | 新建 | 推荐为兽药GMP合 | 2 | | | 限公司 | 类) 生产线(动态) | | 格生产线 | | 此次认证由广东省农业农村厅组织专家团队评审完成，审查内容覆盖生产车间、设备设施、化验室、仓库等全链条环节，并严格依据新版《兽药GMP证 书》标准进行考核。鹏佑生物凭借规范化的管理流程、完善的硬件设施及专业化的团队操作，顺利通过 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 7月1日，原颇尔全球副总裁兼中国区总经理陈淮（Andy）正式出任贝克曼库尔特医学诊断全球副总裁兼中国区总经 理。 与此同时，原贝克曼库尔特临床诊断全球副总裁、中国区总经理陈 小穗（Rosa Chen）将全面聚焦丹纳赫中国医学诊 断平台的整体运营管理工作，继 续担任平台总裁职务。 陈淮将直接向陈小穗汇报，同时强虚线汇报给贝克曼库尔特医学诊断全球总裁Kev in O'Rei l y。 陈淮 2019年5月加入丹纳赫，拥有丰富的跨行业管理经验。在加入丹纳赫之前，他曾在精密制造领域领先企业梅特勒-托利 多担任多个关键管理职位，涵盖销售、市场营销及高级总经理等职务。他毕业于南京理工大学，拥有中欧国际工商学院 MBA学位。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 互 联 网 仪 器 信 息 网 | 责 编 ： 满 ...

Core Viewpoint - The credit rating agency maintains a stable outlook for the company, indicating improvements in its core business of food safety rapid testing and animal diagnostics, despite challenges in its in vitro diagnostics segment [3][6]. Financial Performance - The company's total debt as of March 2025 is 4.76 billion, up from 1.19 billion in 2022, reflecting ongoing project funding needs [3][6]. - Revenue for 2024 is projected at 2.24 billion, a decline from 2.54 billion in 2023, primarily due to reduced performance in the in vitro diagnostics segment [3][6]. - The company reported a net profit of -0.04 billion for 2024, indicating continued financial challenges [4][6]. Business Operations - The company focuses on food safety rapid testing and animal diagnostics, with a significant contract signed with Chr. Hansen A/S expected to positively impact future revenues [3][6]. - The company has a strong liquidity position, with a quick ratio of 5.16 and a cash-to-short-term debt ratio of 14.31, indicating manageable short-term debt pressures [3][6]. - The company is expanding its international market presence, with a 15.92% increase in international business revenue in 2024 [15][16]. Industry Context - The domestic food safety rapid testing industry is still in its early stages, with a compound annual growth rate of 25.24% expected, driven by increasing regulatory demands and technological advancements [10][11]. - The global food safety testing market is projected to reach 33.7 billion by 2028, growing at a CAGR of 8.2%, highlighting significant growth potential for the industry [10][11]. - The company is positioned as a leader in the domestic market, with a low market share in the rapidly growing food safety rapid testing sector [10][11].

根据中国证券监督管理委员会《关于同意杭州奥泰生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕495 号）核准同意，公司首次公开 发行人民币普通股 13,500,000 股，每股发行价格为人民币 133.67 元，募集资金 总额为 1,804,545,000.00 元；扣除发行费用 161,278,093.75 元后，募集资金 净额为 1,643,266,906.25 元，上述资金已全部到位，经致同会计师事务所（特 殊普通合伙）审验并出具致同验字【2021】第 332C000116 号《验资报告》。募 集资金到账后，已全部存放于经公司董事会批准开设的募集资金专项账户内，公 司已与保荐机构、存放募集资金的商业银行签署了募集资金三方监管协议。具体 情况详见公司 2021 年 3 月 24 日披露于上海证券交易所网站（www.sse.com.cn） 的《杭州奥泰生物技术股份有限公司首次公开发行股票科创板上市公告书》。 公司首次公开发行股票募集资金扣除发行费用后拟投资于以下项目： 单位：万元 | 序号 | 项目名称 | 项目总投资 | 募集资金投资额 | | --- | --- | --- | ...

Core Viewpoint - After a significant increase in stock price, major shareholders of Hotgen Biotech (688068.SH) plan to reduce their holdings to cash out [2][11]. Shareholder Reduction Plans - Shareholder Zhou Xin intends to reduce his holdings by no more than 1.94% of the company's total shares, equating to 180,000 shares, within three months [3][4]. - Zhou Xin currently holds 7.34% of Hotgen Biotech's shares, amounting to 680,660 shares [4]. - If the maximum reduction is executed at the closing price of 137.30 CNY per share on June 25, Zhou Xin could cash out approximately 247 million CNY [5][6]. Historical Context of Shareholder Reductions - Zhou Xin's planned reduction follows a similar pattern observed in 2021, where he and other shareholders executed high-level cash-outs after stock price surges [8][12]. - In 2021, Zhou Xin reduced his holdings from 10.35% to 8.48%, cashing out approximately 102 million CNY at prices ranging from 36.89 to 199.5 CNY per share [10]. Recent Performance and Financials - Hotgen Biotech's stock price has surged approximately fivefold from 23.08 CNY per share on September 23, 2024, to 137.30 CNY per share on June 25, 2024 [7]. - The company has experienced significant financial distress, reporting a loss of 191 million CNY in 2024 and a further loss of 24 million CNY in the first quarter of the same year [17][18]. - Revenue has declined sharply from 35.57 billion CNY in 2022 to 5.11 billion CNY in 2024, marking a decrease of 84.78% year-on-year [17]. Business Operations and Market Position - Hotgen Biotech specializes in in vitro diagnostics (IVD) and has seen fluctuating performance due to the COVID-19 pandemic, with revenues peaking at 5.14 billion CNY in 2020 [15][16]. - The company has been involved in the development of various COVID-19 testing products, which initially drove significant revenue growth [15]. - However, as the pandemic subsided, the company's revenue and net profit have sharply declined, leading to concerns about its future profitability [17][18]. Research and Development Trends - The company's R&D investment has been decreasing, with expenditures dropping from 191 million CNY in 2022 to 113 million CNY in 2024 [18]. - Despite the decline in financial performance, the company has invested in several innovative pharmaceutical companies, although these ventures have yet to yield profits [18].

华经产业研究院为助力企业、科研、投资机构等单位了解兽用诊断试剂行业发展态势及未来趋势，特重 磅推出《2025-2031年中国兽用诊断试剂行业发展全景监测及投资策略研究报告》，本报告由华经产业 研究院研究团队对兽用诊断试剂行业进行多年跟踪研究，使用桌面研究与定量调查、定性分析相结合的 方式，全面解读兽用诊断试剂行业市场，深度挖掘行业潜在商机；科学运用研究模型，多维度对行业投 资风险进行评估后精心研究编制。 兽用诊断试剂是用于动物疾病诊断、监测、检疫以及动物机体生理指标检测等的生物制品或化学试剂， 在动物疫病防控、养殖管理等方面具有重要作用。兽用诊断试剂是动物疫病防控和兽医科技发展的核心 元素之一。经二十多年发展，历经化学、酶、免疫测定和探针技术4次技术革命，我国兽用诊断试剂行 业逐步发展，目前已有了行业自身明确的分类标准。 随着畜牧业经济快速增长的同时，动物疫病种类不断增多，动物疫病给畜牧业发展造成的风险日益突 出。目前我国兽用诊断试剂产业虽已初具规模，据统计，2024年我国兽用诊断试剂产量为2.83亿份，需 求量为3.42亿份。 市场规模来看，据统计，我国兽用诊断试剂行业市场规模从2018年的22亿元增长至2 ...

体外诊断是一个高度专业化的领域，对知识的准确性与专业性要求极高。通用大模型在面对高专业、高 规范要求的场景时，往往出现"答非所问"、"理解错误"等问题，难以满足体外诊断对准确性的严苛要 求。受惠于采用本地化的专业向量数据库与算法优化，"易问e答"能够规避通用大模型常见的幻觉、错 乱、冗余等问题。"易问e答"拥有500多份专业文档、近7000页图文并茂的复杂专业内容，涵盖了近2万 个知识点、12万个检索切片的高品质专业知识库。商汤日日新大模型通过深度融合相关知识，训练出高 度贴合使用场景的专用模型，展现"懂行业、会解答"的能力。 商汤作为深度参与医疗行业的AI企业，始终坚守数据安全和合规的底线，携手罗氏诊断推出的"易问e 答"严格遵循医疗行业的安全标准和隐私法规，例如数据脱敏、单租户管理、公安部信息安全等级保护 认证等，为使用者提供安全可靠的服务。此外，该平台具备高度的溯源性，能清晰阐述专业数据的来 源，让客户可以放心使用。 在实际应用中，该平台能够精准解读项目说明中的专业内容，为医生提供详细的诊断依据，帮助医生快 速做出准确的临床决策，提供个性化的诊断建议。经专业人士对于200多条随机提问生成内容作出评 估， ...

央广网郑州6月27日消息（记者 郝振青）合规经营是企业发展的生命线。在河南省郑州经济技术开发 区，郑州安图生物工程股份有限公司（以下简称 "安图生物"）将"合规"植入进研发、生产、销售乃至 财务管理的每一个环节，实现从票据审核、费用报销到税务申报的全链条智能管控。 全链合规管控：助力企业高质量发展 "我们公司新人入职的'第一课'，便是通过模拟真实业务场景的报销流程实训、票据合规性实战演练， 让'合规意识'如同基因般融入每位员工的职业血脉。"安图生物相关负责人说，该公司的管理层将合规 决策纳入日常管理，每月召开的"合规决策情景模拟"，使每个流程都嵌入合规责任清单，让税务合规从 财务部门的"独角戏"变为全公司的"大合唱"。 作为体外诊断行业领军企业，安图生物始终将供应商合规管理视为激活产业链高质量发展的核心引擎。 从供应商的资质准入、纳税信用审查，到生产运营、质量管控等综合维度，安图生物均设置了严苛的筛 选标准。凭借这套科学严谨的体系，安图生物不仅保障了自身供应链的安全稳定，更通过 "以点带面" 的方式，引导上下游企业共同增强合规意识。 "严格的供应商信用管理既是供应链保障，更是行业合规发展的引擎。"安图生物采购 ...

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

25 省中成药集采落地 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 相关报告 10% 医药生物 沪深300 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/6/13-2025/6/26） 业 周 报 医药生物行业 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% -40% -20% 0% 20% 行 业 研 究 22-03 22-05 22-07 22-09 22-11 23-01 23-03 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 6 月 27 日 分析师：谢雄雄 SAC 执业证书编 ...